Mark Pepin, MD, PhD

Fellowships, grants and career support – Postdoctoral Fellowships – EMBO Supporting internationally mobile postdoctoral researchers in Europe and around the world

Looking for a #LifeSciences postdoctoral #opportunity? 🧪 Have a look at the EMBO Postdoctoral Fellowships for internationally mobile scientists in #Europe and globally.

Apply before 11 July: www.embo.org/funding/fell...
#research #funding #postdoc

Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets - Nature Reviews Cardiology In this Review, Mericskay and colleagues discuss the role of cardiac intermediary metabolism in heart failure, describing the perturbations in cardiac energy metabolism that occur in heart failure wit...

Four Reviews on Metabolic alterations in heart failure, free for 1 month!
Cardiac intermediary metabolism: doi.org/10.1038/s415...
Vascular dysfunction: doi.org/10.1038/s415...
Immunometabolism: doi.org/10.1038/s415...
Mechano-energetic uncoupling: doi.org/10.1038/s415...

Gendefekt der Maus deckt neues HFpEF-Therapiekonzept auf!

Professorship in Human Genetics (W3) (f/m/d) - Cologne, Nordrhein-Westfalen (DE) job with Faculty of Medicine // University of Cologne | 12839753 Professorship in Human Genetics (W3) (f/m/d) Faculty of Medicine University of Cologne, including the directorship of the Institute for Human Genetics

Job Alert: Professorship in Human Genetics

Univeristy of Cologne is searching for a new head for human genetics.

www.nature.com/naturecareer...

CXCL12 drives natural variation in coronary artery anatomy across diverse populations Coronary dominance is a clinically important developmental phenotype that dictates whether the left or right coronary arteries perfuse the back of the heart. Genome-wide association studies and downst...

Just read this lovely paper in @cellpress.bsky.social by @tassimes.bsky.social and colleagues. Nice work! www.cell.com/cell/fulltex...

I must say, as a physician-scientist trainee, that this meeting has evolved into THE meeting to attend for relevant advice/mentoring, feedback, and networking opportunities…. We need it now more than ever. Thank you so much for making it possible!

So great to hangout! Let’s do it again next year!

Impact of Cholesterol on Cardiac Mitochondrial Function | Circulation Research

Despite the tragedy of his untimely passing, it is exciting to continue learning from Dr. Lopaschuk’s seasoned perspective on all things cardiac metabolism…
www.ahajournals.org/doi/10.1161/...

“Adaptive, resilient, curious, essential.” Descriptors given by our @the-asci.bsky.social panel discussing the value of physician-scientist trainees

Welcome to the 2025 AAP/ASCI/APSA Joint Meeting! We're excited to kick off an inspiring week with physician-scientist leaders, trainees & mentors. Be sure to connect, explore, and tag us along the way! Let’s make it a great one. See you around the conference!

“Dog ate my suit,” and a day before @the-asci.bsky.social. Maybe it was time for an upgrade anyway!

Integrative Analysis of Single-Cell Transcriptomics and Genetic Associations Identify Cell States Associated with Vascular Disease Vascular diseases are accompanied by alterations in cellular phenotypes which underly disease pathogenesis, with single-cell technologies aiding in th…

Excited to see this in-press! Using single-nuclear RNA-seq & GWAS integration, we can implicate vascular cell types that both enrich CAD risk loci and undergo phenotypic cell state transitions. www.sciencedirect.com/science/arti...

Going home for the holidays is such a wonderful privilege; here's a glimpse of our first time in years!

Indeed, poor data abound in this clinical space. These data suggest that half of the HFrecEF who attempt withdrawing GDMT would ultimately benefit from resuming it, but why not try it?

That number is not entirely true for HFrecEF, as reported by Hammer et al. (pubmed.ncbi.nlm.nih.gov/37451602/). Considering HFrEF GDMT costs our patients $100/month on average (after insurance). If a 8 week divergence, why not offer trial-of-withdrawal with a 3-month follow-up?

Sadly, this is a single-center pilot study of 51 patients, so not exactly the evidence I'd need to make conclusions. Even still, (1) less than half of their HFrecEF patients relapsed and (2) no clinical outcomes? Maybe everyone deserves a trial of withdrawal?

Is there any hard evidence for or against GDMT in HFrEF patients with a recovered EF?

"sTAT CoNSuLt cArDioLOgY"

One of these days I'll go... or maybe host my own PepCon.

Nice work!

Loved reading this. Truly raising the standard, @jengreitz.bsky.social

O-GlcNAcylation modulates expression and abundance of N-glycosylation machinery in an inherited glycosylation disorder Matheny-Rabun and colleagues discover that O-GlcNAc modification of rate-limiting enzymes within the N-glycosylation pathway impacts their function, drawing a connection between two spatially separate...

O-GlcNAc modification of enzymes within the N-glycosylation pathway impacts their function, revealing a connection between these two distinct glycosylation pathways.
www.cell.com/cell-reports...

Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease | NEJM Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the LAMP2 protein. In male patients, the predomina...

Phase I results of AAV delivery of LAMP2B in Danon disease reported yesterday at #AHA24 & NEJM www.nejm.org/doi/full/10....

These are remarkable results and while it is early days, this represents new hope for millions of patients worldwide with severe inherited cardiovascular disease. Congrats to the entire team of investigators.

For more on these disorders, see med.stanford.edu/familyheart